AIM ImmunoTech Announces That Analysis Of AMP-518 Complete Clinical Patient Data Underscores Ampligen's Potential To Improve The Post-COVID Condition Of Fatigue, And That This Would Be The Likely Subject Population For AIM's Planned Follow-up Clinical...
AIM ImmunoTech Announces That Analysis Of AMP-518 Complete Clinical Patient Data Underscores Ampligen's Potential To Improve The Post-COVID Condition Of Fatigue, And That This Would Be The Likely Subject Population For AIM's Planned Follow-up Clinical...
aim immunotech宣佈對AMP-518完整的臨床患者數據進行分析，強調Ampligen改善後COVID疲勞症狀的潛力，並表示這將是AIM計劃中後續臨床研究的研究對象群體。
AIM ImmunoTech Announces That Analysis Of AMP-518 Complete Clinical Patient Data Underscores Ampligen's Potential To Improve The Post-COVID Condition Of Fatigue, And That This Would Be The Likely Subject Population For AIM's Planned Follow-up Clinical Trial
AiM ImmunoTech 宣佈，對 AMP-518 完整臨床患者數據的分析凸顯了 Ampligen 改善後疲勞狀況的潛力，這將是 AIM 計劃中的後續臨床試驗的受試者群體
AIM ImmunoTech Inc. (NYSE:AIM) ("AIM") today announced that an analysis of the complete clinical patient data from the AMP-518 clinical trial supported the Company's belief in Ampligen as a potential therapeutic for people with the moderate-to-severe Post-COVID condition of fatigue, and that this would be the likely subject population for AIM's planned follow-up clinical trial.
AiM ImmunoTech Inc.（紐約證券交易所代碼：AIM）（「AIM」）今天宣佈，對來自 AMP-518 臨床試驗的完整臨床患者數據的分析支持了該公司的信念，即Ampligen是COVID後中度至重度疲勞症狀患者的潛在治療藥物，這將是AIM計劃的後續臨床試驗的受試者群體。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。